-
UBS Downgrades Avadel Pharmaceuticals (AVDL) to Neutral
-
H.C. Wainwright Downgrades Avadel Pharmaceuticals (AVDL) to Neutral
-
Leerink Partners Downgrades Avadel Pharmaceuticals (AVDL) to Market Perform
-
RBC Capital on Jazz Pharmaceuticals (JAZZ): 'we would be buyers on the potential upcoming positive ph.III zanidatimab data in GEA'
-
Jefferies Downgrades Avadel Pharmaceuticals (AVDL) to Hold
-
Needham Downgrades Avadel Pharmaceuticals (AVDL) to Hold
-
Avadel Pharma (AVDL) Halted, News Pending
-
Increasing unusual call option volume: BYND AVDL REI GLL LEVI BRR ALC ACHV
-
Avadel and Jazz Pharmaceuticals settle patent litigation for $90 million
-
Avadel Pharma (AVDL) 5K contracts of October 12.50 puts trade
-
Avadel Pharmaceuticals (AVDL) PT Raised to $36 at H.C. Wainwright
-
Avadel licenses valiloxybate from XWPharma for $20 million upfront
-
Avadel Pharmaceuticals (AVDL) PT Raised to $20 at UBS
-
Avadel Pharmaceuticals (AVDL) PT Raised to $24 at H.C. Wainwright
-
Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue
-
ASL Strategic Value Fund urges Avadel shareholders to vote against directors
-
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders (AVDL)
-
Avadel Pharma (AVDL) Receives Orphan Drug Designation from FDA for LUMRYZ for ER Oral Suspension for the Treatment of Idiopathic Hypersomnia
-
Avadel Pharma (AVDL) Appoints Susan Rodriguez as COO
-
Avadel Pharma (AVDL) Tops Q1 EPS by 1c ; Offers Guidance
-
Avadel Pharma (AVDL) announces favorable ruling in LUMRYZ case
-
Avadel Pharma (AVDL) Provides Update at Needham Virtual Healthcare Conference
-
H.C. Wainwright Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL)
-
Oppenheimer Reiterates Outperform Rating on Avadel Pharmaceuticals (AVDL)
-
Avadel Pharma (AVDL) Misses Q4 EPS by 3c ; Offers Guidance
-
Avadel Pharma (AVDL) Appoints Kevin Springman as VP of Sales
-
Deutsche Bank Starts Avadel Pharmaceuticals (AVDL) at Buy
-
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL) Board
-
Avadel Pharmaceuticals (AVDL) PT Slashed to $13 at Piper Sandler; 'Lowering PT But Staying Bullish'
-
After-hours movers: NVIDIA, Costco, Penguin Solutions, Avadel Pharma
-
Avadel Pharma (AVDL) Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
-
Piper Sandler Provides 'Expert Perspectives On Orexin Agonists And An Evolving Sleep/Wake Space'
-
Avadel Pharmaceuticals (AVDL) PT Lowered to $25 at H.C. Wainwright
-
Avadel Pharma (AVDL) Tops Q3 EPS by 5c
-
Avadel Pharmaceuticals (AVDL) PT Raised to $30 at Oppenheimer
-
Avadel Pharma (AVDL) Announces Favorable Ruling in Administrative Procedure Act Litigation
-
H.C. Wainwright Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL)
-
Avadel Pharma (AVDL) Announces FDA Approval of LUMRYZ Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with N
-
Avadel Pharma (AVDL) Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing
-
H.C. Wainwright Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL)
-
Increasing unusual put option volume: AVDL BBWI OIH HA FL JWN BCS KSS KMX LUNR BEN STNE
-
Avadel Pharma (AVDL) announces court decision allowing commercial launch of LUMRYZ in narcolepsy to proceed without interruption
-
Avadel Pharma (AVDL) Tops Q2 EPS by 4c
-
Here are Oppenheimer’s best Smidcap ideas

